Search results for: 'gene elderly'

World Health Organization statistics state that by 2030, one out of six people will be 60 years of age or more. The aged population will likely increase from 1 billion in 2020 to 1.4 billion in 2030 and 2.1 billion by 2050. The senior population typically experiences a gradual decrease in physical and mental capacity. This causes a high disease and...

19 Jan 2023  |  Global  |  Technology Research

Advances in Gene Editing Technologies in Healthcare

Next-generation genome editing tools and improved delivery are bolstering gene editing therapeutics and diagnostics.

Infographics

×

Advancements in gene editing technology are boosting its adoption in various fields, including healthcare, diagnostics, agriculture, and industrial biotechnology. CRISPR, ZFNs, and TALENs are examples of technologies that have revolutionized the gene editing field. Moreover, with constant research efforts, new technologies such as base editing, pri...

The global CGT therapeutics market is transitioning from a niche, high-complexity segment into a mainstream, high-growth therapeutic class. Driven by scientific breakthroughs, accelerated regulatory pathways, and the entry of next-generation platforms—including in vivo CRISPR gene editing, allogeneic “off-the-shelf” cell therapies, and automated sm...

The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...

The drug approvals of Yescarta (axicabtagene ciloleucel), Luxturna (Voretigene neparvovec) and Kymriah (Tisagenlecleucel) have turned a leaf in the pharmaceutical chapter of gene therapy development. Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme repl...

16 Aug 2022  |  North America  |  Market Research

Global Cell and Gene Therapy (CGT) Growth Opportunities

The Shift to Prevalent Diseases and Allogeneic Cell Therapies Creates New Growth Opportunities in the CGT Value Chain

Infographics

×

This Frost & Sullivan study examines the global cell and gene therapy (CGT) market. It highlights revenue forecasts and key growth opportunities for CGT market participants based on the evolution of their business models and strategic approaches as well as investments and regulations. The study segments the market by product (cell therapy, gene-mod...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping biomanufacturing, cell and gene therapy, precision immunotherapy, anti-infectives, and neurotherapeutics across oncology, infectious disease, nephrology, and neurodegenerative disease. It hi...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides strategic insights into frontier innovations redefining therapeutic development, precision diagnostics, and immune modulating interventions. It showcases breakthroughs across engineered phage therapeutics, intracellular peptide platforms, advanced gene ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming respiratory medicine, liver regeneration, metabolic disease management, infectious disease therapeutics, neurological disorders, cardiovascular risk reduction, oncology workflows, and nex...